SCHEMBL20598142

SCHEMBL20598142

O=c1cc(C(Cl)(Cl)Cl)oc2ccc(Cl)cc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADCY1 Q08828 1/20 1.00
MAPT P10636 4/20 0.69
HTT P42858 2/20 0.69
ALDH1A1 P00352 4/20 0.55
TNKS O95271 1/20 0.54
ADORA3 P0DMS8 1/20 0.54
GABRP O00591 8/20 0.53
GABRD O14764 8/20 0.53
GABRA1 P14867 8/20 0.53
GABRB1 P18505 8/20 0.53
GABRG2 P18507 8/20 0.53
GABRB3 P28472 8/20 0.53
GABRA5 P31644 8/20 0.53
GABRA3 P34903 8/20 0.53
GABRA2 P47869 8/20 0.53
GABRB2 P47870 8/20 0.53
GABRA4 P48169 8/20 0.53
GABRE P78334 8/20 0.53
GABRA6 Q16445 8/20 0.53
GABRG1 Q8N1C3 8/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27821368 0.75 ADCY1 (0.60) ADCY1MAPTALDH1A1TNKSADORA3
SCHEMBL4650588 0.72 GABRP (0.82) MAPTALDH1A1TNKSADORA3GABRP
SCHEMBL27582566 0.72 ADCY1 (0.57) ADCY1MAPTALDH1A1TNKSADORA3
SCHEMBL4092241 0.71 TTR (0.71) ADCY1MAPTALDH1A1TNKSADORA3
SCHEMBL1504213 0.71 ALDH1A1 (1.00) ADCY1ALDH1A1TNKSADORA3GABRP
SCHEMBL13437399 0.71 KDM4E (0.56) ADCY1MAPTALDH1A1TNKSADORA3
SCHEMBL5191884 0.71 ALDH1A1 (0.77) ADCY1MAPTALDH1A1TNKSADORA3
SCHEMBL12324681 0.71 ADCY1 (0.55) ADCY1MAPTALDH1A1TNKSADORA3
SCHEMBL6957384 0.71 ADCY1 (0.55) ADCY1MAPTALDH1A1TNKSADORA3
SCHEMBL27840766 0.71 MAOB (0.56) ADCY1MAPTALDH1A1TNKSADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240366586-A1 METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-11-07 US claimed
WO-2023034413-A2 METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-03-09 WO claimed
US-12414949-B2 Pyrazolyl pyrimidinone compounds and the uses thereof PURDUE RESEARCH FOUNDATION (US) 2025-09-16 US disclosed
US-20240366586-A1 METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-11-07 US disclosed
US-20240083877-A1 NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE PURDUE RESEARCH FOUNDATION (US) 2024-03-14 US disclosed
US-20230293523-A1 PYRAZOLYL PYRIMIDINONE COMPOUNDS AND THE USES THEREOF PURDUE RESEARCH FOUNDATION (US) 2023-09-21 US disclosed
US-20230250084-A1 PYRAZOLYL PYRIMIDINONE COMPOUNDS AND THE USES THEREOF PURDUE RESEARCH FOUNDATION (US) 2023-08-10 US disclosed
US-11690844-B2 Pyrazolyl pyrimidinone compounds and the uses thereof PURDUE RESEARCH FOUNDATION (US) 2023-07-04 US disclosed
US-11667623-B2 Scaffold of adenylyl cyclase inhibitors for chronic pain and opioid dependence PURDUE RESEARCH FOUNDATION (US) 2023-06-06 US disclosed
WO-2023034413-A2 METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-03-09 WO disclosed
US-20210100797-A1 PYRAZOLYL PYRIMIDINONE COMPOUNDS AND THE USES THEREOF PURDUE RESEARCH FOUNDATION (US) 2021-04-08 US disclosed
US-20200239447-A1 NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE PURDUE RESEARCH FOUNDATION (US) 2020-07-30 US disclosed
US-10662176-B2 Scaffold of adenylyl cyclase inhibitors for chronic pain and opioid dependence PURDUE RESEARCH FOUNDATION (US) 2020-05-26 US disclosed
US-20200031785-A1 METHODS FOR TREATING CHRONIC PAIN AND OPIOID DEPENDENCE USING ADENYLYL CYCLASE INHIBITORS PURDUE RESEARCH FOUNDATION (US) 2020-01-30 US disclosed
US-10457653-B2 Adenylyl cyclase inhibitors for chronic pain and opioid dependence PURDUE RESEARCH FOUNDATION (US) 2019-10-29 US disclosed
US-20190023688-A1 NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE PURDUE RESEARCH FOUNDATION (US) 2019-01-24 US disclosed
US-20190002418-A1 ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE PURDUE RESEARCH FOUNDATION (US) 2019-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200239447-A1 NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE CAP1, ADCY1, ADCYAP1R1 ADCY1 2/4885MAPT 3579/4885HTT 3708/4885
US-20190002418-A1 ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE CAP1, OPRK1, OPRL1 ADCY1 4/4885MAPT 3534/4885HTT 4041/4885
US-20240083877-A1 NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE CAP1, ADCY1, ADCYAP1R1 ADCY1 2/4885MAPT 3579/4885HTT 3708/4885
US-12414949-B2 Pyrazolyl pyrimidinone compounds and the uses thereof CAP1, ADCY1, ADCYAP1R1 ADCY1 2/4885MAPT 3370/4885HTT 2598/4885
US-10457653-B2 Adenylyl cyclase inhibitors for chronic pain and opioid dependence CAP1, ADCY1, OPRK1 ADCY1 2/4885MAPT 3356/4885HTT 4193/4885
US-20190023688-A1 NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE CAP1, ADCY1, ADCYAP1R1 ADCY1 2/4885MAPT 3579/4885HTT 3708/4885
US-20200031785-A1 METHODS FOR TREATING CHRONIC PAIN AND OPIOID DEPENDENCE USING ADENYLYL CYCLASE INHIBITORS ADCY1, CAP1, ADCY2 ADCY1 1/4885MAPT 3262/4885HTT 3451/4885
US-11667623-B2 Scaffold of adenylyl cyclase inhibitors for chronic pain and opioid dependence CAP1, ADCY1, ADCYAP1R1 ADCY1 2/4885MAPT 3085/4885HTT 3138/4885
US-11690844-B2 Pyrazolyl pyrimidinone compounds and the uses thereof CAP1, ADCY1, ADCYAP1R1 ADCY1 2/4885MAPT 3370/4885HTT 2598/4885
US-20230250084-A1 PYRAZOLYL PYRIMIDINONE COMPOUNDS AND THE USES THEREOF CAP1, ADCY1, ADCYAP1R1 ADCY1 2/4885MAPT 3370/4885HTT 2598/4885
US-20230293523-A1 PYRAZOLYL PYRIMIDINONE COMPOUNDS AND THE USES THEREOF CAP1, ADCY1, ADCYAP1R1 ADCY1 2/4885MAPT 3370/4885HTT 2598/4885
US-20210100797-A1 PYRAZOLYL PYRIMIDINONE COMPOUNDS AND THE USES THEREOF CAP1, ADCY1, ADCYAP1R1 ADCY1 2/4885MAPT 3370/4885HTT 2598/4885
US-20240366586-A1 METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE IL15, IL2, IL17A ADCY1 1732/4885MAPT 1073/4885HTT 3082/4885
US-10662176-B2 Scaffold of adenylyl cyclase inhibitors for chronic pain and opioid dependence CAP1, ADCY1, ADCYAP1R1 ADCY1 2/4885MAPT 3085/4885HTT 3138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.